Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Glottic carcinoma presents unique treatment challenges.
• Optimizing local control while minimizing toxicity is crucial for laryngeal preservation.

Purpose of the Study:

• To evaluate the feasibility, efficacy, and toxicity of concurrent chemoradiotherapy using S-1 for T2N0 glottic carcinoma.
• To assess the local control rates and adverse events associated with this treatment regimen.

Main Methods:

• A cohort of 23 patients with T2N0 glottic carcinoma received concurrent chemoradiotherapy with S-1.
• Radiotherapy involved a median dose of 70 Gy (2 Gy/fraction, 5 fractions/week).
• S-1 was administered at 65 mg/m(2)/day for 4 weeks, followed by a 2-week break, and then twice daily until radiotherapy completion.

Main Results:

• Complete initial local control of the primary tumor was achieved in all patients.
• The 3-year local control rate was 95.4% after a median follow-up of 38 months.
• The most common grade 3 adverse events included mucositis (13 patients) and dysphagia (2 patients). No grade 4 acute or severe late toxicities were observed.

Conclusions:

• Concurrent chemoradiotherapy with S-1 is a feasible and well-tolerated treatment option for T2N0 glottic carcinoma.
• This regimen demonstrates high efficacy in achieving local tumor control.
• Chemoradiotherapy with S-1 is a promising therapeutic strategy for improving outcomes in T2N0 glottic carcinoma.